摘要
We investigated the variability in the PFT （platelet function test） response to CYP2C19 polymorphisms and compared it with the clinical presentation. Furthermore, running cost analyses were done. One-hundred and seventy Saudi Arabian patients who were stable on 75 mg clopidogrel for ≥1 month for various cardiac indications were enrolled. We extracted DNA using the MagNA Pure LC instrument. CYP2C19 genotyping for the alleles, ＊1, ＊2 and ＊3, was conducted by real-time PCR （polymerase chain reaction）. The PFT was carried out by VerifyNow P2Y12 assay for all patients. Clinical events were documented retrospectively for all patients. One hundred and seventeen patients presented with the wild variant 1/1, 19 patients with 1/2, and 34 patients with 2/2. We could not detect ＊3. There was a significant association between different genotyping and percentage inhibitions （P = 0.0002）. 1/1 patients tended to be moderate-to-extensive metabolisers, whereas most of the other patients were slow metabolisers. The cost of doing the PFT was 250 SR （Saudi Riyals）/patient and 200 SR/patient for kits and materials （excluding equipment and labour）. The PFT varied considerably with polymorphisms, but showed no significant associations with clinical symptoms.
